Dr Reddy'sReddy's Laboratories settled a patent dispute with Indivior Inc. and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction.
A US court dismissed all claims and counterclaims with prejudice on June 28, 2022, pursuant to a joint stipulation of dismissal filed by the parties, the Hyderabad-based drug major said in a statement.
The stipulation of dismissal was filed pursuant to a settlement agreement that the company entered into with Indivior and Aquestive, it added.
The settlement and dismissal resolves all claims between the parties, including Indivior's and Aquestive's patent infringement, as well as the company's antitrust counterclaim against Indivior, Dr Reddy said.
Dr Reddy'sReddy's announced on June 24 that it will receive payments totalling USD 72 million by March 31, 2024 as a result of a settlement agreement with Indivior Inc and Aquestive Therapeutics.
The agreement resolves all claims made by the parties relating to the company's generic buprenorphine and naloxone sublingual film, 2 mg 0.5 mg, 4 mg 1 mg, 8 mg 2 mg and 12 mg 3 mg dosages.
Buprenorphine and naloxone sublingual film medication is used to treat opioid dependence or addiction.